CXCR4 and ovarian cancer: The resulting BSA-PTX nanoparticles selectively internalized into CXCR4+ ovarian cancer cells, showing excellent biodistribution and significant inhibition of tumour growth and metastasis in vivo by a dual drug delivery and CXCR4-blocking mechanism [266].